FDA approves AbbVie 24-hour Parkinson’s treatment, Sage Therapeutics axes workforce, FDA halts Novavax's COVID-flu vax trials [The good, the bad, the ugly]

Off Script: A Pharma Manufacturing Podcast

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:

The good — FDA approves AbbVie 24-hour Parkinson’s treatment

The bad — Sage Therapeutics axes workforce

The ugly — FDA halts Novavax's COVID-flu vaccine trials